FRED A. MIDDLETON - 23 Jan 2024 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Role
Director, 10%+ Owner
Signature
/s/ John Dunn, Attorney-in-Fact
Issuer symbol
CALC
Transactions as of
23 Jan 2024
Net transactions value
+$2,600,003
Form type
4
Filing time
25 Jan 2024, 20:00:34 UTC
Previous filing
20 Nov 2023
Next filing
22 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CALC Common Stock Purchase $900,904 +243,356 +35% $3.70 946,744 23 Jan 2024 By Sanderling Venture Partners VI, LP F1, F2
transaction CALC Common Stock Purchase $535,591 +144,676 +25% $3.70 727,433 23 Jan 2024 By Sanderling Venture Partners VI Co-Investment Fund, L.P. F1, F3
transaction CALC Common Stock Purchase $719,935 +194,472 +81% $3.70 435,148 23 Jan 2024 By Sanderling Ventures VII, L.P. F1, F4
transaction CALC Common Stock Purchase $188,920 +51,032 +81% $3.70 114,260 23 Jan 2024 By Sanderling Ventures VII (Canada), L.P. F1, F5
transaction CALC Common Stock Purchase $48,807 +13,184 +91% $3.70 27,609 23 Jan 2024 By Sanderling Ventures VII Annex Fund, L.P. F1, F4
transaction CALC Common Stock Purchase $14,512 +3,920 +22% $3.70 21,602 23 Jan 2024 By Sanderling Ventures Management VI F1, F3
transaction CALC Common Stock Purchase $106,410 +28,744 +1857% $3.70 30,292 23 Jan 2024 By Sanderling Ventures Management VII F1, F5
holding CALC Common Stock 11,714 23 Jan 2024 Direct
holding CALC Common Stock 8,176 23 Jan 2024 By Golden Triangle Ventures, LLC F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CALC Warrant Purchase $15,210 +121,678 $0.1250* 121,678 23 Jan 2024 Common Stock 121,678 $5.36 By Sanderling Venture Partners VI, LP F1, F3, F7
transaction CALC Warrant Purchase $15,210 +121,678 $0.1250* 121,678 23 Jan 2024 Common Stock 121,678 $7.15 By Sanderling Venture Partners VI, LP F1, F3, F8
transaction CALC Warrant Purchase $9,042 +72,338 $0.1250* 72,338 23 Jan 2024 Common Stock 72,338 $5.36 By Sanderling Venture Partners VI Co-Investment Fund, L.P. F1, F3, F7
transaction CALC Warrant Purchase $9,042 +72,338 $0.1250* 72,338 23 Jan 2024 Common Stock 72,338 $7.15 By Sanderling Venture Partners VI Co-Investment Fund, L.P. F1, F3, F8
transaction CALC Warrant Purchase $12,154 +97,236 $0.1250* 97,236 23 Jan 2024 Common Stock 97,236 $5.36 By Sanderling Ventures VII, L.P. F1, F5, F7
transaction CALC Warrant Purchase $12,154 +97,236 $0.1250* 97,236 23 Jan 2024 Common Stock 97,236 $7.15 By Sanderling Ventures VII, L.P. F1, F5, F8
transaction CALC Warrant Purchase $3,190 +25,516 $0.1250* 25,516 23 Jan 2024 Common Stock 25,516 $5.36 By Sanderling Ventures VII (Canada), L.P. F1, F5, F7
transaction CALC Warrant Purchase $3,190 +25,516 $0.1250* 25,516 23 Jan 2024 Common Stock 25,516 $7.15 By Sanderling Ventures VII (Canada), L.P. F1, F5, F8
transaction CALC Warrant Purchase $824 +6,592 $0.1250* 6,592 23 Jan 2024 Common Stock 6,592 $5.36 By Sanderling Ventures VII Annex Fund, L.P. F1, F5, F7
transaction CALC Warrant Purchase $824 +6,592 $0.1250* 6,592 23 Jan 2024 Common Stock 6,592 $7.15 By Sanderling Ventures VII Annex Fund, L.P. F1, F5, F8
transaction CALC Warrant Purchase $245 +1,960 $0.1250* 1,960 23 Jan 2024 Common Stock 1,960 $5.36 By Sanderling Ventures Management VI F1, F3, F7
transaction CALC Warrant Purchase $245 +1,960 $0.1250* 1,960 23 Jan 2024 Common Stock 1,960 $7.15 By Sanderling Ventures Management VI F1, F3, F8
transaction CALC Warrant Purchase $1,796 +14,372 $0.1250* 14,372 23 Jan 2024 Common Stock 14,372 $5.36 By Sanderling Ventures Management VII F1, F5, F7
transaction CALC Warrant Purchase $1,796 +14,372 $0.1250* 14,372 23 Jan 2024 Common Stock 14,372 $7.15 By Sanderling Ventures Management VII F1, F5, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
F2 The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI, LP ("SVP VI, LP", together with Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F3 The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F4 The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the "Sanderling VII Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F5 The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F6 The Reporting Person is a managing member of Golden Triangle Ventures LLC and may be deemed to beneficially own the securities of the Issuer held by Golden Triangle Ventures LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F7 The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
F8 The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.